🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Pravastatina Kern Pharma 40 mg comprimidos EFG, Placebo Pravastatina

    The George Institute

    intrauterine growth restriction, preeclampsia

    phase 3 small molecule active

    1 trial

  2. Prednisolon 1 mg JENAPHARM, Prednisolon 5 mg JENAPHARM, Prednisolone placebo-5mg, Prednisolon 20 mg JENAPHARM, Prednisolone placebo-10mg, Prednisolon 10 mg JENAPHARM, Upadacitinib placebo, Upadacitinib, Prednisolone placebo-20mg, Prednisolone placebo-1mg, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  3. Prednisolon STADA® 5 mg Tabletten, Prednisolone placebo hard capsule and tablet, Normal Saline, Prednisolon STADA® 10 mg Tabletten, [1-13C]SODIUM ACETATE, Avalotcagene ontaparvovec

    Lacuna Pharma Pty Ltd

    Late-onset Ornithine transcarbamylase (OTC) deficiency

    phase 3 small molecule active

    1 trial

  4. Prednisolon STADA® 5 mg Tabletten, Prednisolone placebo hard capsule, 10 mg, Prednisolone Placebo hard capsule, 5mg, Prednisolon STADA® 10 mg Tabletten, Pariglasgene brecaparvovec, Normal Saline

    Lacuna Pharma Pty Ltd

    Glycogen Storage Disease Type Ia (GSDIa)

    phase 3 small molecule active

    1 trial

  5. ProAir® Digihaler®, Placebo TEV-56248, Albuterol Sulfate HFA, ArmonAir® Digihaler®, Fluticasone propionate,Salbutamol sulfate

    Lacuna Pharma Pty Ltd

    Asthma

    phase 3 small molecule active

    1 trial

  6. RILUTEK 50 mg film-coated tablets, masitinib, Placebo to 200mg masitinib, masitinib, Riluzole Zentiva 50 mg film-coated tablets, Placebo to 100mg masitinib

    AB Science

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  7. RIMEGEPANT SULFATE, Placebo to rimegepant sulfate

    Pfizer Australia Pty Ltd

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  8. RITUXIMAB , SODIUM CHLORIDE, Placebo for lenalidomide 25mg, PREDNISONE , MINJUVI 200 mg powder for concentrate for solution for infusion, PREDNISOLONE , LENALIDOMIDE, DOXORUBICIN , Placebo for lenalidomide 10mg, VINCRISTINE , LENALIDOMIDE, Placebo for lenalidomide 15mg, LENALIDOMIDE, CYCLOPHOSPHAMIDE

    Incyte

    Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  9. RO7046015, Placebo Prasinezumab

    Hoffmann-La Roche

    Early-Stage Parkinson’s Disease (PD)

    phase 3 small molecule active

    1 trial

  10. RO7046015, RO7046015, RO7046015 Placebo

    Hoffmann-La Roche

    Early Parkinson's disease

    phase 3 small molecule active

    1 trial

  11. RO7790121 Placebo, RO7790121

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  12. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  13. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  14. RO7795068, RO7795068, RO7795068 Placebo, RO7795068, RO7795068, RO7795068, RO7795068

    Hoffmann-La Roche

    Obesity or Overweight and Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  15. RO7795068, RO7795068, RO7795068, RO7795068, RO7795068, RO7795068 Placebo, RO7795068

    Hoffmann-La Roche

    Obesity or Overweight Without Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  16. ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  17. ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN

    Novartis Pharmaceuticals

    Non-obstructive Coronary Artery Disease

    phase 3 small molecule active

    1 trial

  18. Ramelteon and Placebo (9 possible combinations total)

    Takeda

    Chronic Insomnia

    phase 3 small molecule completed

    1 trial

  19. Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules

    Gedeon Richter Plc.

    Adolescent Patients (13 to 17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

  20. Remternetug, Placebo to match LY

    Eli Lilly Co.

    Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  21. Retifanlimab (INCMGA00012), CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Bendatax 6 mg/ ml, Placebo liquid (not containing the active substance, otherwise identical to INCMGA0012)

    Incyte

    Squamous Carcinoma of the Anal Canal

    phase 3 small molecule active

    1 trial

  22. Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s

    Incyte

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  23. Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib

    Syndax Pharmaceuticals

    Newly Diagnosed AML with an NPM1 mutation

    phase 3 small molecule active

    1 trial

  24. Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources